Sickle cell disease (SCD) is a genetic disorder characterized by abnormality in the oxygen-carrying protein hemoglobin. The gene mutation underlying the disease results in the amino acid valine…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The 2013-2015 FDA…
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China. The prevalence of this chronic disease remains high owing to the presence of a large…
Last Updated 8 December 2015 The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high…
Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…
Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…
Tackling the Market Access Challenges in Brazil, Mexico, and Argentina Increases in seroprevalent cases of hepatitis C virus (HCV), disease awareness, and patient access to HCV treatment create…
How Will Healthcare Reform and Payer-Led Cost-Containment Strategies Impact U.S. Prescribing? The market opportunity for hepatitis C virus (HCV) features a large prevalent population, a…
Pancreatic cancer (PaC) is one of the most aggressive and highly lethal solid malignancies, with a 5-year survival of only 5%. Treatment of PaC is largely dependent on tumor size and location…
A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to small…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…
The Impact of Premium-Priced Market Entrants on MCO-Run Medicare and Medicaid Plans The groundbreaking therapies for the Hepatitis C virus (HCV) promise high cure rates for millions of Americans…
How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public…
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…